Journals / Batı Karadeniz Tıp Dergisi / 2021 / Cilt: 5 - Sayı: 2

Epidemiology, Treatment Options and Survival Analysis in Glioblastoma Multiforme: A Retrospective Single Center Study

Glioblastome Multiforme Epidemiyolojisi, Tedavi Seçenekleri ve Sağkalım Süresi: Retrospektif Tek Merkezli Çalışma

Pages
248–255
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: As a result of our study, it was observed that age and combined treatment options are important prognostic factors in patients with GBM.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Glioblastoma multiforme (GBM) is the most common of primary brain tumors.
📊
Key Findings & Data:Material and Methods:In this study, 72 patients diagnosed with GBM between 2017-2019 in Zonguldak Bülent Ecevit University Faculty of Medicine Department of Brain and Neurosurgery were evaluated retrospectively.
💡
Conclusion & Impact:Conclusion: As a result of our study, it was observed that age and combined treatment options are important prognostic factors in patients with GBM.
🔬Design:Research Article
📍Scope:2017-2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Glioblastoma multiforme (GBM) is the most common of primary brain tumors. Although there are many clinical and experimental studies about its treatment; options for treatment of GBM have not changed much. Our study was planned to examine the relationship between epidemiologies, treatment options and survival times of patients with GBM. Material and Methods:In this study, 72 patients diagnosed with GBM between 2017-2019 in Zonguldak Bülent Ecevit University Faculty of Medicine Department of Brain and Neurosurgery were evaluated retrospectively. These patients’ treatment modalities, epidemiologies and survival times were examined. Results: 28 of the patients are female, 44 of them are male, 55.6% of them are over the age of 60. The difference in survival. The relationship between gender and survival time is not revealing (p=0.303>0.05) It was observed that the survival time decreased by 28.9% with increasing age. While GBM was observed most frequently temporoparietal settlement as localization, there was no significant difference between tumor localization and survival time. Conclusion: As a result of our study, it was observed that age and combined treatment options are important prognostic factors in patients with GBM.

Özet

Amaç: Glioblastoma multiforme (GBM), primer beyin tümörlerinin en sık görülenidir. Tedavisi ile ilgili çok sayıda klinik ve deneysel çalışma yapılmasına rağmen; GBM’in tedavi seçenekleri çok fazla değişmemiştir. Çalışmamız, GBM’li hastaların epidemiyolojisi, tedavi seçenekleri ve sağkalım süreleri arasındaki ilişkiyi incelemek amacıyla planlandı. Gereç ve Yöntemler: Bu çalışmada, 2017-2019 yılları arasında Zonguldak Bülent Ecevit Üniversitesi Tıp Fakültesi Beyin ve Sinir Cerrahisi Anabilim Dalı’nda GBM tanısı alan 72 hasta retrospektif olarak değerlendirilmiştir. Bu hastaların tedavi modaliteleri, epidemiyolojileri ve sağkalım süreleri incelenmiştir. Bulgular: Hastaların 28’i kadın, 44’ü erkek olup, %55,6’sı 60 yaş üstüdür. Cinsiyet ile sağkalım süresi arasındaki fark istatistiksel olarak anlamlı değildir (p=0,303>0,05). Yaş arttıkça sağkalım süresinde %28,9 oranında azalış olduğu görülmüştür. GBM lokalizasyon olarak en sık temporopariyatel yerleşimli olduğu gözlenirken, tümör lokalizasyonu ile sağkalım süresi arasında anlamlı fark görülmedi. Sonuç: Çalışmamızın sonucunda GBM’li hastalarda, yaşın ve kombine tedavi seçeneğinin önemli bir prognostik faktörler olduğu görülmüştür.

🔖

Cite This Article

KESKİN, E., ELMAS, Ö., AYDIN, H. A., Şimşek, K., GÜN, E. G., KALAYCI, M. (2022). Epidemiology, Treatment Options and Survival Analysis in Glioblastoma Multiforme: A Retrospective Single Center Study. Batı Karadeniz Tıp Dergisi, Cilt: 5 - Sayı: 2, 248–255. https://ajindex.com/articles/463122

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane, Australia: Codon Publications; 2017.
  2. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2012;19(4):764-772
  3. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella- Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131(6):803-820
  4. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz- Sloan JS. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro-Oncology 2020;22(Supplement_1):1-96
  5. Altinoz MA, Nalbantoglu J, Ozpinar A, Ozcan ME, Del Maestro RF, Elmaci I. From epidemiology and neurodevelopment to antineoplasticity. Medroxyprogesterone reduces human glial tumor growth in vitro and C6 glioma in rat brain in vivo. Clin Neurol Neurosurg 2018;173:20-30
  6. Shahcheraghi SH, Zangui M, Lotfi M, Ghayour-Mobarhan M, Ghorbani A, Jaliani HZ, Sadeghnia HR, Sahebkar A. Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Curr Pharm Des 2019;25(3):333-342
  7. Huang B, Zhang H, Gu L, Ye B, Jian Z, Stary C, Xiong X. Advances in immunotherapy for glioblastoma multiforme. J Immunol Res 2017;1-11
  8. Von Neubeck C, Seidlitz A, Kitzler HH, Beuthien-Baumann B, Krause M. Glioblastoma multiforme: Emerging treatments and stratification markers beyond new drugs. Br J Radiol 2015;88(1053):20150354
  9. Hamisch C, Ruge M, Kellermann S, Kohl AC, Duval I, Goldbrunner R, Grau SJ. Impact of treatment on survival of patients with secondary glioblastoma. JJ Neurooncol 2017;133(2):309-313
  10. Ahmadipour Y, Kaur M, Pierscianek D, Gembruch O, Oppong MD, Mueller O, Jabbarli R, Glas M, Sure U, El Hindy N. Association of surgical resection, disability, and survival in patients with glioblastoma. J Neurol Surg A Cent Eur Neurosurg 2019;80(04):262-268
  11. Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003;145(1):5-10
  12. Salgado MV, Torres J, Esteban J, Gutiérrez JA, Ley L, Carrato A. Survey of treatment recommendations for elderly patients with glioblastoma. Clin Transl Oncol 2020;22:1329-1334